Roth Capital Issues Pessimistic Outlook for TSE:TRU Earnings

Trulieve Cannabis Corp. (TSE:TRU) – Equities research analysts at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for shares of Trulieve Cannabis in a research report issued on Thursday, May 8th. Roth Capital analyst W. Kirk now expects that the company will earn ($0.14) per share for the quarter, down from their prior estimate of ($0.12). Roth Capital currently has a “Strong-Buy” rating on the stock. Roth Capital also issued estimates for Trulieve Cannabis’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.58) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.34) EPS.

A number of other equities research analysts also recently weighed in on the company. Cormark raised Trulieve Cannabis from a “hold” rating to a “moderate buy” rating in a research report on Monday, March 3rd. Craig Hallum raised Trulieve Cannabis to a “strong-buy” rating in a report on Wednesday, February 26th.

Trulieve Cannabis Stock Performance

About Trulieve Cannabis

TransUnion provides risk and information solutions. The company operates in three segments: U.S. Markets, International, and Consumer Interactive. The U.S. Markets segment provides consumer reports, actionable insights, and analytics to businesses. These businesses use its services to acquire new customers; assess consumer ability to pay for services; identify cross-selling opportunities; measure and manage debt portfolio risk; collect debt; verify consumer identities; and mitigate fraud risk.